ATE259650T1 - Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen - Google Patents
Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinenInfo
- Publication number
- ATE259650T1 ATE259650T1 AT96926873T AT96926873T ATE259650T1 AT E259650 T1 ATE259650 T1 AT E259650T1 AT 96926873 T AT96926873 T AT 96926873T AT 96926873 T AT96926873 T AT 96926873T AT E259650 T1 ATE259650 T1 AT E259650T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- lipids
- preparations
- reducing
- blood levels
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000001130 gallstones Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51626395A | 1995-08-17 | 1995-08-17 | |
| PCT/US1996/012674 WO1997006816A1 (en) | 1995-08-17 | 1996-08-02 | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE259650T1 true ATE259650T1 (de) | 2004-03-15 |
Family
ID=24054813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96926873T ATE259650T1 (de) | 1995-08-17 | 1996-08-02 | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20020147142A1 (de) |
| EP (1) | EP0865294B1 (de) |
| JP (1) | JP4173913B2 (de) |
| AT (1) | ATE259650T1 (de) |
| AU (1) | AU6688896A (de) |
| CA (1) | CA2229450A1 (de) |
| DE (1) | DE69631605T2 (de) |
| DK (1) | DK0865294T3 (de) |
| ES (1) | ES2216055T3 (de) |
| MX (1) | MX9801159A (de) |
| PT (1) | PT865294E (de) |
| WO (1) | WO1997006816A1 (de) |
| ZA (1) | ZA966798B (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| CA2224867A1 (en) * | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| US5830450A (en) * | 1996-06-19 | 1998-11-03 | Lallone; Roger L. | Compositions of leptin bound to an apolipoprotein |
| US7332338B2 (en) | 1996-10-04 | 2008-02-19 | Lexicon Pharmaceuticals, Inc. | Vectors for making genomic modifications |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
| US6436707B1 (en) | 1998-03-27 | 2002-08-20 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
| US6808921B1 (en) | 1998-03-27 | 2004-10-26 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| JP4199421B2 (ja) * | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| CA2388417A1 (en) * | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| AU2002359288B2 (en) | 2001-10-22 | 2008-07-31 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| EP1462116A1 (de) * | 2003-03-29 | 2004-09-29 | Villitech SARL | Zubereitung zur Behandlung des Magen-Darm-Traktes |
| GB0307367D0 (en) * | 2003-03-29 | 2003-05-07 | Twg | Composition and method for treating the gastro-intestinal tract |
| AU2004313245B2 (en) | 2003-12-30 | 2011-04-14 | Durect Corporation | Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| US7629315B2 (en) * | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| RS58010B1 (sr) | 2012-09-27 | 2019-02-28 | Childrens Medical Ct Corp | Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| HUE063647T2 (hu) | 2016-09-12 | 2024-01-28 | Amryt Pharmaceuticals Inc | Eljárások anti-leptin semlegesítõ antitestek detektálására |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
-
1996
- 1996-08-02 AT AT96926873T patent/ATE259650T1/de not_active IP Right Cessation
- 1996-08-02 DE DE69631605T patent/DE69631605T2/de not_active Expired - Fee Related
- 1996-08-02 EP EP96926873A patent/EP0865294B1/de not_active Expired - Lifetime
- 1996-08-02 JP JP50931997A patent/JP4173913B2/ja not_active Expired - Fee Related
- 1996-08-02 AU AU66888/96A patent/AU6688896A/en not_active Abandoned
- 1996-08-02 PT PT96926873T patent/PT865294E/pt unknown
- 1996-08-02 DK DK96926873T patent/DK0865294T3/da active
- 1996-08-02 WO PCT/US1996/012674 patent/WO1997006816A1/en not_active Ceased
- 1996-08-02 MX MX9801159A patent/MX9801159A/es not_active IP Right Cessation
- 1996-08-02 CA CA002229450A patent/CA2229450A1/en not_active Abandoned
- 1996-08-02 ES ES96926873T patent/ES2216055T3/es not_active Expired - Lifetime
- 1996-08-12 ZA ZA9606798A patent/ZA966798B/xx unknown
-
2001
- 2001-05-07 US US09/850,433 patent/US20020147142A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX9801159A (es) | 1998-05-31 |
| CA2229450A1 (en) | 1997-02-27 |
| AU6688896A (en) | 1997-03-12 |
| EP0865294B1 (de) | 2004-02-18 |
| WO1997006816A1 (en) | 1997-02-27 |
| US20020147142A1 (en) | 2002-10-10 |
| JP4173913B2 (ja) | 2008-10-29 |
| JPH11511165A (ja) | 1999-09-28 |
| EP0865294A1 (de) | 1998-09-23 |
| ES2216055T3 (es) | 2004-10-16 |
| DE69631605T2 (de) | 2005-01-05 |
| ZA966798B (en) | 1997-02-19 |
| DK0865294T3 (da) | 2004-06-28 |
| PT865294E (pt) | 2004-07-30 |
| DE69631605D1 (de) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE259650T1 (de) | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen | |
| ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| DE69822496D1 (de) | Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen | |
| ATE198050T1 (de) | Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia | |
| ATE275383T1 (de) | Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen | |
| DE69827192D1 (de) | Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen | |
| DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| ATE195527T1 (de) | Neue steroidester zur behandlung von hauterkrankungen | |
| DE69636147D1 (de) | Verfahren zur herstellung von phosphorothioat-oligomeren | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE69722426D1 (de) | Isobutylgaba und dessen derivate zur schmerzbehandlung | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| DE69802918D1 (de) | Vwf propeptide enthaltendes pharmazeutisches präparat | |
| DE69829217D1 (de) | Vorrichtung zur therapeutischen behandlung von blutgefässen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE59611383D1 (de) | Darreichungsform zur applikation von pharmazeutischen wirkstoffen und hilfsstoffen und verfahren zur herstellung derselben | |
| ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| DE69829995D1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE69522685D1 (de) | Behandlung von blut-plasma | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0865294 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |